InvestSMART

Pro Medicus Limited (ASX: PME) - Announcements

Current share price for PME : $175.340 4.05 (2.26%)+

ASX company news and announcements for Pro Medicus Limited (PME) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pro Medicus Limited (PME) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pro Medicus Limited (PME), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pro Medicus Limited (PME)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18,318 Interview with CEO - Full year results 18 Aug 2021 9:38AM $56.500 $175.340 risen by 210.34%
$18,318 Dividend/Distribution - PME 18 Aug 2021 9:18AM $56.500 $175.340 risen by 210.34%
$18,318 PME Full year results 18 Aug 2021 9:13AM $56.500 $175.340 risen by 210.34%
$18,318 Full Year Statutory Accounts 18 Aug 2021 9:13AM $56.500 $175.340 risen by 210.34%
$18,318 Preliminary Final Report 18 Aug 2021 9:10AM $56.500 $175.340 risen by 210.34%
$18,318 PME Results release date & webcast conference 21 Jul 2021 9:29AM $59.470 $175.340 risen by 194.84%
$18,318 Audit Committee structure 17 Jun 2021 10:28AM $53.500 $175.340 risen by 227.74%
$18,318 PME signs Research Collaboration Agreement with Mayo Clinic 3 Jun 2021 9:28AM $46.150 $175.340 risen by 279.93%
$18,318 PME signs A$14M, 8 year deal with University of Vermont 13 May 2021 9:40AM $40.560 $175.340 risen by 332.30%
$18,318 On market share buy-back 1 Apr 2021 9:36AM $41.330 $175.340 risen by 324.24%
$18,318 PME Cleansing Notice - Founder sell down - AH 22 Feb 2021 10:02AM $47.000 $175.340 risen by 273.06%
$18,318 PME Cleansing Notice - Founder sell down SH 22 Feb 2021 9:45AM $47.000 $175.340 risen by 273.06%
$18,318 Change of Director's Interest Notice - Anthony Hall 19 Feb 2021 9:02AM $45.970 $175.340 risen by 281.42%
$18,318 Change of Director's Interest Notice - Sam Hupert 19 Feb 2021 9:01AM $45.970 $175.340 risen by 281.42%
$18,318 Sale of 1M shares each by founders 19 Feb 2021 9:00AM $45.970 $175.340 risen by 281.42%
$18,318 HY2021 Results Presentation 17 Feb 2021 10:39AM $42.120 $175.340 risen by 316.29%
$18,318 CEO Interview - 1H21 results 17 Feb 2021 10:22AM $41.830 $175.340 risen by 319.17%
$18,318 Dividend/Distribution - PME 17 Feb 2021 9:39AM $45.650 $175.340 risen by 284.10%
$18,318 Company Announcement - Interim Results 17 Feb 2021 9:35AM $45.650 $175.340 risen by 284.10%
$18,318 Half Year Accounts 17 Feb 2021 9:34AM $45.650 $175.340 risen by 284.10%
$18,318 Appendix 4D 17 Feb 2021 9:33AM $45.650 $175.340 risen by 284.10%
$18,318 PME signs A$31M - 7 year deal with major US Health System 16 Feb 2021 10:22AM $46.450 $175.340 risen by 277.48%
$18,318 PME HY results release date 5 Feb 2021 10:36AM $43.200 $175.340 risen by 305.88%
$18,318 PME receives FDA approval for Breast Density Algorithm 2 Feb 2021 10:13AM $42.880 $175.340 risen by 308.91%
$18,318 CEO Interview - Intermountain deal 14 Jan 2021 10:37AM $34.670 $175.340 risen by 405.74%

326 - 350 of 679 results

Page 14 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.